These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33481423)

  • 21. Targeting the gut microbiota for the treatment of irritable bowel syndrome.
    Herndon CC; Wang YP; Lu CL
    Kaohsiung J Med Sci; 2020 Mar; 36(3):160-170. PubMed ID: 31782606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of abuse and mood on bowel symptoms and health-related quality of life in irritable bowel syndrome (IBS).
    Kanuri N; Cassell B; Bruce SE; White KS; Gott BM; Gyawali CP; Sayuk GS
    Neurogastroenterol Motil; 2016 Oct; 28(10):1508-17. PubMed ID: 27151081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Irritable Bowel Syndrome, Emotion Regulation, and Gut Microbiota].
    Fukudo S
    Brain Nerve; 2016 Jun; 68(6):607-15. PubMed ID: 27279158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for using serotonergic agents to treat irritable bowel syndrome.
    Baker DE
    Am J Health Syst Pharm; 2005 Apr; 62(7):700-11; quiz 712-3. PubMed ID: 15790796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients.
    Mikocka-Walus A; Turnbull D; Moulding N; Wilson I; Andrews JM; Holtmann G
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1137-43. PubMed ID: 18070012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.
    Yan R; Murphy M; Genoni A; Marlow E; Dunican IC; Lo J; Andrew L; Devine A; Christophersen CT
    BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32816830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome.
    Niewinna K; Zielińska A; Fichna J
    Expert Opin Pharmacother; 2020 Jan; 21(1):73-84. PubMed ID: 31724881
    [No Abstract]   [Full Text] [Related]  

  • 29. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.
    Vork L; Weerts ZZRM; Mujagic Z; Kruimel JW; Hesselink MAM; Muris JWM; Keszthelyi D; Jonkers DMAE; Masclee AAM
    Neurogastroenterol Motil; 2018 Feb; 30(2):. PubMed ID: 28804974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irritable bowel syndrome: a gut microbiota-related disorder?
    Bhattarai Y; Muniz Pedrogo DA; Kashyap PC
    Am J Physiol Gastrointest Liver Physiol; 2017 Jan; 312(1):G52-G62. PubMed ID: 27881403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care.
    Engsbro AL; Begtrup LM; Kjeldsen J; Larsen PV; de Muckadell OS; Jarbøl DE; Bytzer P
    Am J Gastroenterol; 2013 Jun; 108(6):972-80. PubMed ID: 23419383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
    Brenner DM; Sayuk GS
    Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What impact do Rome IV criteria have on patients with IBS in China?
    Wang B; Zhao W; Zhao C; Jin H; Zhang L; Chen Q; Wang B
    Scand J Gastroenterol; 2019 Dec; 54(12):1433-1440. PubMed ID: 31829752
    [No Abstract]   [Full Text] [Related]  

  • 36. The Role of Acupuncture on the Gut-Brain-Microbiota Axis in Irritable Bowel Syndrome.
    Yaklai K; Pattanakuhar S; Chattipakorn N; Chattipakorn SC
    Am J Chin Med; 2021; 49(2):285-314. PubMed ID: 33622207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome.
    Wang Z; Xu CM; Liu YX; Wang XQ; Zhang L; Li M; Zhu SW; Xie ZJ; Wang PH; Duan LP; Zhu HQ
    Chin Med J (Engl); 2019 Apr; 132(8):889-904. PubMed ID: 30958430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping.
    Nakajima S; Takahashi K; Sato J; Fukuda M; Yamamoto K; Inoue T; Okumura Y; Fujiyama Y
    J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S138-43. PubMed ID: 20586856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irritable bowel syndrome and gut microbiota.
    Canakis A; Haroon M; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):28-35. PubMed ID: 31789724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.